GSE180677 Microarray analysis of correlates of vaccine immunogenecity following ALVAC vaccination in NHP in Study 36

Contributors : Jeffrey A Tomalka ; Adam-Nicolas Pelletier ; Slim Fourati ; Muhammad B Latif ; Ashish Sharma ; Kathryn Furr ; Kevin Carlson ; Michelle Lifton ; Ana Gonzalez ; Peter Wilkinson ; Genoveffa Franchini ; Robert Parks ; Norman Letvin ; Nicole L Yates ; Kelly E Seaton ; Georgia Tomaras ; Jim Tartaglia ; Merlin Robb ; Nelson Michael ; Richard Koup ; Barton Haynes ; Sampa Santra ; Rafick-Pierre S ékalySeries Type : Expression profiling by arrayOrganism : Homo sapiens ; Macaca mulattaThe RV144 HIV vaccine trial remains the only study to demonstrate significant protection from future HIV-1 acquisition. One of the key components of the RV144 vaccine was the use of the canarypox vector ALVAC as the priming component. Since AIDSVAX, the booster component, alone failed to provide protection we hypothesized that the ALVAC prime contributed significantly to the generation of protection. To test this, we designed a NHP immunogenicity trial to mechanistically link ALVAC vaccination with the magnitude of V1V2 titers, the most significant immune correlate of reduced HIV-1 acquisition in RV144. Our objective was to use a systems biology approach to identify the transcription factors, target genes and immune pathways which were being induced by ALVAC vaccination and associated with higher V1V2 titers. We identified the transcription factor CREB1 and its target genes as rapidly induced by ALVAC in multiple immune subsets and that CREB1 drives the expression and act...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Macaca mulatta Source Type: research